🟢 Regeneron Pharmaceuticals is trading 4% up today after Q2 earnings beat and upgraded margin outlook

Regeneron Pharmaceuticals is trading at $723.48 (+4.03%) after reporting second-quarter results that beat Wall Street estimates and raising its full-year profitability guidance.

• The company posted $4.29 billion in revenue and $14.29 in non-GAAP EPS, driven by strong performance from key products Dupixent and EYLEA HD.
• Management upgraded the full-year non-GAAP gross margin outlook to 84%–85%, providing a clear catalyst for the stock's upward movement.